Pharma in Focus - knowledge is power

15 Dec 08 - 18 Jan 09

Uncertain times and future hopes - rounding up 2008
This year began with a new government, continued with PBS reform, ended with an economic crisis and saw more than a few company restructures along the way. We sum up 2008 and look forward to 2009

Why won't Mr Rudd trust the PBAC?
This week we again report on the extended delays to PBS listings of cancer drugs arising from the Cabinet approval process. The issue is an important one for many reasons but at bottom, while Finance Department bureaucrats comb through submissions already passed by the Pharmaceutical Benefits Advisory Committee, patients die

Subscribe to Pharma in Focus

Sign Up Now

What you'll pay

A two week trial of Pharma in Focus is FREE of charge.

Paid subscription to Pharma in Focus costs $319.95 per year. This can be substantially reduced if you qualify for our LOYALTY BONUS*

3 Simple Steps

	Fill in your details below and submit
	Make your subscription choice*
	Make your payment choice (Visa, MasterCard, Invoice)

*LOYALTY BONUS:
If your organisation already has paid-up subscribers, we offer a substantial loyalty bonus on additional subscriptions. Our system will check when you enter your details below.

Email Address
Retype your Email Address
First Name
Last name
Company or Organisation
Position
Phone
Send me News Alerts as	HTML (colourful) OR Text only

Note: When your subscription has expired we hope you will renew it but we will continue to send you the weekly Pharma in Focus News Alert whether you renew or not. You can unsubscribe from this service at any time. Access: Full text access is immediate. Privacy policy: The list on which your email address appears is protected and will not be sold or passed on to any other organisation or individual.

TOP | BACK

Frustration grows at drug delays
..full report

Delaat drives home PBS message
..full report

Aussie registry missing big trials
..full report

TGA in line for unwanted Xmas gift
..full report

FDA rulings push up CSL's costs
..full report

Private hospitals could drop scripts
..full report

Woolworths disrupts OTC pricing
..full report

Obesity hope for Bayer testosterone
..full report

Price disclosure 'a work in progress'
..full report

NPS warns of tramadol confusion
..full report